Larvol Veri

BIOMARKER:

EGFR amplification

Entrez ID:

1956

Related biomarkers:

‹

›

EGFR amplification EGFR amplification	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR amplification EGFR amplification	Squamous Cell Carcinoma of Head and Neck SCCHN	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR amplification EGFR amplification	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2
EGFR amplification EGFR amplification	Glioblastoma GBM	ABT-414 Sensitive: C2 – Inclusion Criteria ABT-414 Sensitive : C2
EGFR amplification EGFR amplification	Glioblastoma GBM	lapatinib Sensitive: C2 – Inclusion Criteria lapatinib Sensitive : C2
EGFR amplification EGFR amplification	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2
EGFR amplification EGFR amplification	Glioblastoma GBM	KD019 Sensitive: C2 – Inclusion Criteria KD019 Sensitive : C2
EGFR amplification EGFR amplification	Squamous Cell Carcinoma of Head and Neck SCCHN	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
EGFR amplification EGFR amplification	Gastric Cancer Gastric Cancer	cetuximab Sensitive: C3 – Early Trials cetuximab Sensitive : C3
EGFR amplification EGFR amplification	Glioblastoma GBM	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
EGFR amplification EGFR amplification	Melanoma Melanoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3
EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
EGFR amplification EGFR amplification	Colorectal Cancer CRC	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
EGFR amplification EGFR amplification	Colorectal Cancer CRC	panitumumab Sensitive: C3 – Early Trials panitumumab Sensitive : C3
EGFR amplification EGFR amplification	Non Small Cell Lung Cancer NSCLC	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3
EGFR amplification EGFR amplification	Solid Tumor Solid Tumor	ABSK-091 Sensitive: C3 – Early Trials ABSK-091 Sensitive : C3
EGFR amplification EGFR amplification	Lung Cancer Lung Cancer	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3
EGFR amplification EGFR amplification	Lung Cancer Lung Cancer	icotinib Resistant: C3 – Early Trials icotinib Resistant : C3
EGFR amplification EGFR amplification	Non Small Cell Lung Cancer NSCLC	bevacizumab + erlotinib Sensitive: C3 – Early Trials bevacizumab + erlotinib Sensitive : C3
EGFR amplification EGFR amplification	Non Small Cell Lung Cancer NSCLC	bevacizumab + gefitinib Sensitive: C3 – Early Trials bevacizumab + gefitinib Sensitive : C3
EGFR amplification EGFR amplification	Lung Adenocarcinoma LUAD	afatinib Sensitive: C4 – Case Studies afatinib Sensitive : C4

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES